Cargando…

[2.2]Paracyclophane‐Based TCN‐201 Analogs as GluN2A‐Selective NMDA Receptor Antagonists

Recent studies have shown the involvement of GluN2A subunit‐containing NMDA receptors in various neurological and pathological disorders. In the X‐ray crystal structure, TCN‐201 (1) and analogous pyrazine derivatives 2 and 3 adopt a U‐shape (hairpin) conformation within the binding site formed by th...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajan, Remya, Schepmann, Dirk, Steigerwald, Ruben, Schreiber, Julian A., El‐Awaad, Ehab, Jose, Joachim, Seebohm, Guiscard, Wünsch, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596836/
https://www.ncbi.nlm.nih.gov/pubmed/34265163
http://dx.doi.org/10.1002/cmdc.202100400
_version_ 1784600476668395520
author Rajan, Remya
Schepmann, Dirk
Steigerwald, Ruben
Schreiber, Julian A.
El‐Awaad, Ehab
Jose, Joachim
Seebohm, Guiscard
Wünsch, Bernhard
author_facet Rajan, Remya
Schepmann, Dirk
Steigerwald, Ruben
Schreiber, Julian A.
El‐Awaad, Ehab
Jose, Joachim
Seebohm, Guiscard
Wünsch, Bernhard
author_sort Rajan, Remya
collection PubMed
description Recent studies have shown the involvement of GluN2A subunit‐containing NMDA receptors in various neurological and pathological disorders. In the X‐ray crystal structure, TCN‐201 (1) and analogous pyrazine derivatives 2 and 3 adopt a U‐shape (hairpin) conformation within the binding site formed by the ligand binding domains of the GluN1 and GluN2A subunits. In order to mimic the resulting π/π‐interactions of two aromatic rings in the binding site, a [2.2]paracyclophane system was designed to lock these aromatic rings in a parallel orientation. Acylation of [2.2]paracyclophane (5) with oxalyl chloride and chloroacetyl chloride and subsequent transformations led to the oxalamide 7, triazole 10 and benzamides 12. The GluN2A inhibitory activities of the paracyclophane derivatives were tested with two‐electrode voltage clamp electrophysiology using Xenopus laevis oocytes expressing selectively functional NMDA receptors with GluN2A subunit. The o‐iodobenzamide 12 b with the highest similarity to TCN‐201 showed the highest GuN2A inhibitory activity of this series of compounds. At a concentration of 10 μM, 12 b reached 36 % of the inhibitory activity of TCN‐201 (1). This result indicates that the [2.2]paracyclophane system is well accepted by the TCN‐201 binding site.
format Online
Article
Text
id pubmed-8596836
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85968362021-11-22 [2.2]Paracyclophane‐Based TCN‐201 Analogs as GluN2A‐Selective NMDA Receptor Antagonists Rajan, Remya Schepmann, Dirk Steigerwald, Ruben Schreiber, Julian A. El‐Awaad, Ehab Jose, Joachim Seebohm, Guiscard Wünsch, Bernhard ChemMedChem Full Papers Recent studies have shown the involvement of GluN2A subunit‐containing NMDA receptors in various neurological and pathological disorders. In the X‐ray crystal structure, TCN‐201 (1) and analogous pyrazine derivatives 2 and 3 adopt a U‐shape (hairpin) conformation within the binding site formed by the ligand binding domains of the GluN1 and GluN2A subunits. In order to mimic the resulting π/π‐interactions of two aromatic rings in the binding site, a [2.2]paracyclophane system was designed to lock these aromatic rings in a parallel orientation. Acylation of [2.2]paracyclophane (5) with oxalyl chloride and chloroacetyl chloride and subsequent transformations led to the oxalamide 7, triazole 10 and benzamides 12. The GluN2A inhibitory activities of the paracyclophane derivatives were tested with two‐electrode voltage clamp electrophysiology using Xenopus laevis oocytes expressing selectively functional NMDA receptors with GluN2A subunit. The o‐iodobenzamide 12 b with the highest similarity to TCN‐201 showed the highest GuN2A inhibitory activity of this series of compounds. At a concentration of 10 μM, 12 b reached 36 % of the inhibitory activity of TCN‐201 (1). This result indicates that the [2.2]paracyclophane system is well accepted by the TCN‐201 binding site. John Wiley and Sons Inc. 2021-08-03 2021-10-15 /pmc/articles/PMC8596836/ /pubmed/34265163 http://dx.doi.org/10.1002/cmdc.202100400 Text en © 2021 The Authors. ChemMedChem published by Wiley-VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Full Papers
Rajan, Remya
Schepmann, Dirk
Steigerwald, Ruben
Schreiber, Julian A.
El‐Awaad, Ehab
Jose, Joachim
Seebohm, Guiscard
Wünsch, Bernhard
[2.2]Paracyclophane‐Based TCN‐201 Analogs as GluN2A‐Selective NMDA Receptor Antagonists
title [2.2]Paracyclophane‐Based TCN‐201 Analogs as GluN2A‐Selective NMDA Receptor Antagonists
title_full [2.2]Paracyclophane‐Based TCN‐201 Analogs as GluN2A‐Selective NMDA Receptor Antagonists
title_fullStr [2.2]Paracyclophane‐Based TCN‐201 Analogs as GluN2A‐Selective NMDA Receptor Antagonists
title_full_unstemmed [2.2]Paracyclophane‐Based TCN‐201 Analogs as GluN2A‐Selective NMDA Receptor Antagonists
title_short [2.2]Paracyclophane‐Based TCN‐201 Analogs as GluN2A‐Selective NMDA Receptor Antagonists
title_sort [2.2]paracyclophane‐based tcn‐201 analogs as glun2a‐selective nmda receptor antagonists
topic Full Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596836/
https://www.ncbi.nlm.nih.gov/pubmed/34265163
http://dx.doi.org/10.1002/cmdc.202100400
work_keys_str_mv AT rajanremya 22paracyclophanebasedtcn201analogsasglun2aselectivenmdareceptorantagonists
AT schepmanndirk 22paracyclophanebasedtcn201analogsasglun2aselectivenmdareceptorantagonists
AT steigerwaldruben 22paracyclophanebasedtcn201analogsasglun2aselectivenmdareceptorantagonists
AT schreiberjuliana 22paracyclophanebasedtcn201analogsasglun2aselectivenmdareceptorantagonists
AT elawaadehab 22paracyclophanebasedtcn201analogsasglun2aselectivenmdareceptorantagonists
AT josejoachim 22paracyclophanebasedtcn201analogsasglun2aselectivenmdareceptorantagonists
AT seebohmguiscard 22paracyclophanebasedtcn201analogsasglun2aselectivenmdareceptorantagonists
AT wunschbernhard 22paracyclophanebasedtcn201analogsasglun2aselectivenmdareceptorantagonists